Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $1,367,317.00 in Stock

Key Points

• Endurance (Cayman) Ltd Svf, a major shareholder of Vir Biotechnology, sold a total of $1,367,317 worth of shares, reducing their ownership by 1.44% to approximately 15.1 million shares.
• Vir Biotechnology's stock has experienced significant transactions recently, with several insider sales totaling over $5 million within the past two weeks.
• Despite a rough earnings report showing a 60.5% year-over-year revenue decline, analysts have maintained a positive outlook with a target price averaging around $17.30 for the stock.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $6.20, for a total transaction of $1,367,317.00. Following the transaction, the insider owned 15,119,959 shares in the company, valued at approximately $93,743,745.80. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.30, for a total transaction of $690,952.50.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total transaction of $78,348.40.
• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.07, for a total transaction of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.08, for a total transaction of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.14, for a total transaction of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total transaction of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.60, for a total transaction of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.69, for a total transaction of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total transaction of $2,503,901.52.

Vir Biotechnology Price Performance

Shares of VIR stock traded down $0.15 on Wednesday, hitting $6.12. The company's stock had a trading volume of 1,292,552 shares, compared to its average volume of 1,534,586. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $14.45. The firm's fifty day moving average price is $5.24 and its 200-day moving average price is $5.28. The stock has a market capitalization of $850.19 million, a price-to-earnings ratio of -1.53 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $2.38 million. During the same period in the previous year, the firm posted ($1.02) EPS. The firm's revenue for the quarter was down 60.5% on a year-over-year basis. Analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Vir Biotechnology

Several large investors have recently bought and sold shares of the business. ARCH Venture Management LLC acquired a new position in Vir Biotechnology in the second quarter valued at approximately $65,100,000. Orbimed Advisors LLC lifted its holdings in Vir Biotechnology by 5.9% in the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company's stock valued at $11,999,000 after buying an additional 132,466 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Vir Biotechnology by 9.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,374,874 shares of the company's stock valued at $8,909,000 after buying an additional 122,219 shares during the period. Aberdeen Group plc lifted its holdings in Vir Biotechnology by 45.3% in the second quarter. Aberdeen Group plc now owns 1,006,891 shares of the company's stock valued at $5,075,000 after buying an additional 313,699 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company's stock valued at $4,813,000 after buying an additional 225,544 shares during the period. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on VIR. Raymond James Financial began coverage on shares of Vir Biotechnology in a research note on Friday, July 11th. They issued an "outperform" rating for the company. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Vir Biotechnology in a research report on Monday, September 15th. Bank of America raised shares of Vir Biotechnology from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vir Biotechnology in a research report on Tuesday, October 14th. Finally, Evercore ISI assumed coverage on shares of Vir Biotechnology in a report on Wednesday, September 3rd. They set an "outperform" rating and a $12.00 price objective on the stock. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Vir Biotechnology currently has an average rating of "Moderate Buy" and an average target price of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.